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Amyotrophic Lateral Sclerosis Patients
Abstract
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor neurons.
There is a pathological and genetic link between ALS and frontotemporal lobar degeneration (FTLD).
Although FTLD is characterized by abnormal phosphorylated tau deposition, it is unknown whether tau is
phosphorylated in ALS motor neurons. Therefore, this study assessed tau epitopes that are commonly
phosphorylated in FTLD, including serine 396 (pS396), 214 (pS214), and 404 (pS404) in motor neurons
from clinically pure sporadic ALS cases compared with controls. In ALS lower motor neurons, tau pS396
was observed in the nucleus or the nucleus and cytoplasm. In ALS upper motor neurons, tau pS396 was
observed in the nucleus, cytoplasm, or both the nucleus and cytoplasm. Tau pS214 and pS404 was
observed only in the cytoplasm of upper and lower motor neurons in ALS. The number of motor neurons
(per mm2) positive for tau pS396 and pS214, but not pS404, was significantly increased in ALS.
Furthermore, there was a significant loss of phosphorylated tau-negative motor neurons in ALS compared
with controls. Together, our data identified a complex relationship between motor neurons positive for tau
phosphorylated at specific residues and disease duration, suggesting that tau phosphorylation plays a
role in ALS.
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Phosphorylated tau in ALS motor neurons
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Abstract
Amyotrophic lateral sclerosis (ALS) is characterised by the progressive degeneration of
motor neurons. There is a pathological and genetic link between ALS and frontotemporal
lobar degeneration (FTLD). Although FTLD is characterised by abnormal phosphorylated tau
deposition, it is unknown whether tau is phosphorylated in ALS motor neurons. Therefore
this study assessed tau epitopes that are commonly phosphorylated in FTLD, including serine
396 (pS396), 214 (pS214) and 404 (pS404) in motor neurons from clinically pure sporadic
ALS cases compared to controls. In ALS lower motor neurons, tau pS396 was observed in
the nucleus or the nucleus and cytoplasm. In ALS upper motor neurons, tau pS396 was
observed in the nucleus, cytoplasm, or both the nucleus and cytoplasm. Tau pS214 and pS404
was observed only in the cytoplasm of upper and lower motor neurons in ALS. The number
of motor neurons (per mm2) positive for tau pS396 and pS214, but not pS404, was
significantly increased in ALS. Furthermore, there was a significant loss of phosphorylated
tau-negative motor neurons in ALS, compared to controls. Together our data identified a
complex relationship between motor neurons positive for tau phosphorylated at specific
residues and disease duration, suggesting that tau phosphorylation plays a role in ALS.

Keywords (maximum of 7): amyotrophic lateral sclerosis, motor neurone disease,
neurodegeneration, neuropathology, motor neurons, tau, phosphorylation.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by the
progressive degeneration of motor neurons in the brain and spinal cord, leading to widespread
muscle wasting and weakness [1]. Approximately 40% of ALS patients show evidence of
cognitive impairment and 13% fulfil criteria for a clinical diagnosis of frontotemporal
dementia (FTD) [2], which is second only to Alzheimer’s disease (AD) as the most common
cause of early-onset dementia. Frontotemporal lobar degeneration (FTLD) is the term used to
describe the neuropathological forms of FTD [3]. FTLD neuropathology is heterogeneous but
may be broadly divided into 3 subgroups based on the main protein deposits found in the
brains of patients [3]. The three main subgroups are FTLD with tau pathology, tar DNA
binding protein 43 (TDP-43) pathology or FET pathology [3]. ALS and FTLD patients may
show abnormal accumulation of the same proteins in neurons and glial cells (such as TDP-43
and fused in sarcoma), and familial cases may be due to mutations in the same genes (such as
C90RF72) [4]. Together, this suggests that ALS and FTLD are not single disease entities but
are part of a disease spectrum [4].
Approximately 45% of FTLD patients show neuronal and glial inclusions composed of
hyper-phosphorylated tau [4]. Tau has an important role in modulating the assembly and
stability of microtubules, cellular trafficking and maintaining neuronal morphology [5, 6]. In
FTLD with tau pathology and AD, tau becomes progressively hyper-phosphorylated causing
it to detach from the microtubule, eventually forming inclusions including neurofibrillary
tangles (NFTs) in neurons and glial cells [5]. The phosphorylation of key epitopes on the tau
molecule, including serine 214, 396 and 404 have been shown to be promoters of tau
disassembly, aggregation and mislocalisation [7-10]. Tau inclusions in FTLD and AD post
mortem brain tissue and mouse models are positive for these same phosphorylated epitopes
[8, 10-13].
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There have been a number of studies examining tau in the brains of ALS patients. Increased
protein levels and cytoplasmic inclusions positive for tau phosphorylated at various residues,
most notably, threonine 175, 217 and serine 208/210 have been identified throughout the
brains of patients with ALS and cognitive dysfunction, and to a lesser extent in ALS [14-17].
However, motor neurons were not examined. Tau phosphorylated at threonine 175 and 231
has also been identified in hippocampal and spinal cord neurons in ALS with chronic
encephalopathy [18]. Phosphorylated tau (AT8 clone, serine 202/threonine 205) has been
identified in neurons and glia throughout the brain and spinal cord of familial ALS patients
with a mutation in optineurin [19] and in the hippocampal neurons of patients with
ALS/Parkinsonism-Dementia Complex [20]. In addition, in two ALS-FTD patients
presenting with a unique distribution and combination of protein deposits, AT8 tau has also
be identified in the hippocampus and entorhinal cortex neurons [21] and astrocytes [22].
Although the accumulation of a neurotoxic tau45-230 fragment has been identified in ALS motor
neurons, phosphorylated tau epitopes known to be involved in AD and FTLD were not
examined [23]. It was the aim of this study to assess the motor neurons of clinically pure
sporadic ALS cases for accumulation of phosphorylated tau at serine residues 214, 396 and
404 by immunohistochemistry and fibrillar tau (NFTs) by silver staining. Together our data
shows that abnormal tau phosphorylation, but not fibrillar tau is present in both the upper and
lower motor neurons of clinically pure sporadic ALS cases.

Materials and Methods
Case selection
Cases with a pathological diagnosis of sporadic ALS with TDP-43 pathology (n = 8) and ageand-gender matched controls (n = 7) were selected from a neuropathological series collected
by the NSW Brain Banks through regional donor programs in Sydney, Australia. The brain
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donor programs hold approval from the Human Research Ethics Committees of the
University of New South Wales and University of Sydney, and comply with the statement on
human experimentation issued by the National Health and Medical Research Council of
Australia. Patients were diagnosed during life by specialized neurologists using standard
diagnostic criteria [24-26] following a medical interview, cognitive testing and informant
history. Any ALS case with documented clinical FTD symptoms, including cognitive
impairment, was excluded. Any control case with evidence of neurological disease was
excluded. Any ALS or control case with primary and secondary malignancies, head injuries,
history of stroke, inflammatory insults, or family history of neurodegenerative diseases was
excluded. Standardized neuropathological characterization was performed and all ALS cases
demonstrated motor neuron loss and TDP-43 neuronal inclusions in surviving motor neurons.
Demographic, post mortem delay (PMD) and standard neuropathological assessment details
provided by the NSW Brain Banks, as per current guidelines [27-29] are provided for the
individual cases in Table 1. A comparison of the control and ALS cohort demographics and
PMD intervals are provided in Table 2. This research project was approved by the Human
Research Ethics Committee of the University of Wollongong.

Immunohistochemistry
Fresh tissue was fixed in 15% neutral buffered formalin for 2 weeks and transferred to 10%
neutral buffered formalin for long term storage. Formalin was replaced every 2 years to
maintain tissue integrity.

Formalin-fixed, paraffin-embedded tissue sections from the

cervical spinal cord (lower motor neurons) and motor cortex (upper motor neurons) were cut
at a thickness of 10 μm and slide mounted. This is performed by the NSW Brain Banks using
standardized protocols. Routine immunoperoxidase staining was then performed. Briefly,
tissue sections were pretreated with citrate buffer and incubated with primary antibodies
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against tau phosphorylated at serine 396 (pS396 1:500, ab109390, Abcam, Cambridge, UK),
serine 214 (pS214, 1:500, ab170892, Abcam, Cambridge, UK) and serine 404 (pS404, 1:100,
ab92676, Abcam, Cambridge, UK). Sections were then incubated with a biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA), followed by avidin-biotin
tertiary complex (ABC Elite, Vector Laboratories, Burlingame, CA). The reaction product
was visualized using 3, 3’-diaminobenzidine (Sigma-Aldrich, St. Louis, MO) and sections
lightly counterstained with haematoxylin (POCD Healthcare, Artarmon, Australia). For each
phosphorylated tau antibody, both a positive control (inferior temporal cortex from an AD
case) and a negative control (primary antibody omitted) was included. All cases (control,
ALS, positive control and negative control) were stained at the same time using the same indate solutions for each phosphorylated tau epitope. Specificity of the pS396 antibody was
confirmed using a blocking peptide (Abcam,Cambridge, UK) (Supplementary Fig. 1). A
modified Bielschowsky silver stain was used to assess the tissue for protein fibrils, including
NFTs as previously described [30].

Quantitation of tau staining
Brain and spinal cord sections were assessed at 200-400x magnification using the Leica
ICC50 HD microscope camera (Leica, Wetzlar, Germany), images were taken and motor
neurons counted using the cell counter function on Fiji (V1.51n) [31]. To be classified as a
motor neuron, cells had to meet the following criteria: (1) localization within the ventral horn
of the cervical spinal cord or layer V of the motor cortex; (2) greater than or equal to 20µm
in diameter along their longest axis [32]; (3) contain a nucleus identified by haematoxylin.
Tau-positive nuclear staining was classified as “web-like” if the staining overlapped with the
haematoxylin counterstain or “intense” if the staining engulfed the nucleus. The sections
were also visualized using the UV wavelength on a Leica DMi8 microscope (Leica, Wetzlar,
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Germany), supporting that the tau staining observed in the cytoplasm was not lipofuscin. The
Human Brain and Spinal Cord Atlas of England and Wakely was used to identify motor
neurons in the ventral horn of the cervical spinal cord (pages 181, 212, 214) and layer V in
the motor cortex (pages 118, 288) [33]. For each case, the area of the ventral horn in the
spinal cord and layer V in the motor cortex was outlined using the freehand selection tool on
Fiji (V1.51n) and the area determined using the measurement function on Fiji (V1.51n). The
number of motor neurons per mm2 was then determined for each case. The mean number of
motor neurons per mm2 within each group was converted to a percentage, whereby the total
number of control motor neurons per mm2 was 100%. This provides a graphical
representation of the difference in proportion of tau negative to tau positive motor neurons in
controls compared to ALS cases and further demonstrates the loss of motor neurons in ALS
compared to controls. Researchers were blinded to case details during analysis, with
quantitation performed in three cases per region by the same investigator on different days
and by two researchers blind to cases details, to give an intra and inter-rater variance of <5%.

Statistics
Statistical analyses were performed in GraphPad Prism (Version 6, San Diego, CA), with p
<0.05 considered significant. A D’Agostino-Pearson test was first used to test for normality,
revealing that the data was not normally distributed. Therefore, non-parametric Mann
Whitney U tests were used to determine differences in the number of motor neurons per mm2
between ALS and control cases, as well as differences in the number of tau-positive and taunegative motor neurons per mm2 between the ALS and control cases. Differences in the cell
localization of tau pS396 staining within the ALS cohort was determined using a MannWhitney U test for the lower motor neurons and a Kruskal-Wallis with Dunn’s multiple
comparisons test for the upper motor neurons. Spearman rank correlations were performed to
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determine relationships between tau phosphorylation and disease duration, patient age at
death, A score (A/amyloid plaques), B (NFTs) score, C [neuritic plaques (NPs)] score,
TDP-43 stage and Lewy body (LB) stage for ALS cases, and between tau phosphorylation
and ABC scores for controls.

Results
Tau pS396 accumulation in the nucleus and cytoplasm of ALS motor neurons
The number of motor neurons per mm2 was reduced in ALS compared to control cases in
both the spinal cord (lower motor neurons) and motor cortex (upper motor neurons). Four
10m thick sections were analysed, and on average a 53% loss of lower motor neurons was
observed in ALS compared to controls (33.59 x 10-12 mm2 ± 3.95 x 10-12 mm2 vs. 63.75 x
10-12mm2 ± 6.94 x 10-12 mm2, respectively, p = 0.0012), and a 48% loss of upper motor
neurons in ALS compared to controls (19.82 x 10-12 mm2 ± 2.63 x 10-12 mm2 vs. 41.44 x 1012

mm2 ± 6.39 x 10-12 mm2, respectively, p = 0.02). This is in line with previous studies [34,

35].

Tau pS396 was rarely observed in the control spinal cord (Fig. 1A) with only 1.57% ± 1.05%
of total lower motor neurons (positive staining in 2/7 cases) showing weak cytoplasmic
staining. In contrast, tau pS396 staining was identified in the nucleus (Fig. 1B,C), or both the
nucleus and cytoplasm (Fig. 1D) of 92.9% ± 16.5% of ALS lower motor neurons (positive
staining in 8/8 cases). Similarly, tau pS396 was absent from the majority of control upper
motor neurons (Fig. 1E) with 15.55% ± 5.15% of upper motor neurons showing weak
cytoplasmic staining. In contrast, tau pS396 staining was observed in the nucleus (Fig. 1F),
cytoplasm (Fig. 1G), or both the nucleus and cytoplasm (Fig. 1H) of 91.55% ± 17.52% of
upper motor neurons (positive staining in 8/8 cases). The number of tau pS396 positive ALS
10

motor neurons per mm2 was significantly increased from controls in both the spinal cord
(increased 35-fold, p = 0.0003) (Fig. 1I) and motor cortex (increased 4-fold, p = 0.01) (Fig.
1J). The number of tau pS396 negative motor neurons per mm2 was significantly reduced
from controls, in both the spinal cord (reduced 11-fold, p = 0.0003) (Fig. 1I) and motor
cortex (reduced 10-fold, p = 0.006) (Fig. 1J).

Within the ALS cohort, two tau pS396 nuclear morphologies were identified – the most
prevalent was a web-like pattern that overlapped with the haematoxylin counterstain (Fig. 1B,
F), however an intense stain that fully engulfed the nucleus was also observed (Fig. 1C) (now
referred to as ‘web-like’ versus ‘intense’ nuclear pS396 tau; 94.9% ± 2.9% vs. 5.1% ± 0.3%
in the spinal cord; 93.9% ± 2.9% vs. 6.0% ± 0.4% in the motor cortex). The majority of ALS
motor neurons showed an enlarged cytoplasm, consistent with motor neuron swelling [36].
There was a significant increase in the number of ALS lower motor neurons with nuclear
compared to nuclear and cytoplasmic staining (90.0% ± 17.8% vs. 10.0% ± 5.7%, p =
0.0005), however there was no significant difference in pS396 cell localisation in the upper
motor neurons (nuclear = 39.3% ± 9.1%, cytoplasm = 16.9% ± 4.3%, nuclear + cytoplasm =
43.9% ± 10.7%) (Fig. 1K).

Tau pS214 and pS404 accumulation in the cytoplasm of ALS motor neurons
Tau pS214 and pS404 staining was only observed in the cytoplasm of motor neurons. In the
spinal cord, tau pS214 accumulation was minimal in controls affecting 15.6% ± 4.6% of
lower motor neurons (positive staining in 5/7 cases) (Fig. 2A) compared to 87.4% ± 13.5% of
ALS lower motor neurons (positive staining in 8/8 cases) (Fig. 2B). Similarly, in the motor
cortex, only 7.2% ± 2.1% of control upper motor neurons showed tau pS214 staining
(positive staining in 5/7 cases) (Fig. 2C) compared to 88.4% ± 16.2% of ALS upper motor
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neurons (positive staining in 8/8 cases) (Fig. 2D). The number of tau pS214 positive ALS
motor neurons per mm2 was significantly increased from controls in both the spinal cord
(increased 4-fold, p = 0.002) (Fig. 2E) and motor cortex (increased 6-fold, p = 0.001) (Fig.
2F). Similarly, the number of tau pS214 negative neurons per mm2 was significantly reduced
from controls in both the spinal cord (reduced 11-fold, p = 0.0003) (Fig. 2E) and motor
cortex (reduced 15-fold, p = 0.0003) (Fig. 2F).
In the spinal cord, tau pS404 staining was observed in 40.7% ± 11.0% of control lower motor
neurons (positive staining in 7/7 cases) (Fig. 3A) compared to 91.73% ± 29.8% of ALS lower
motor neurons (positive staining in 8/8 cases) (Fig. 3B). In the motor cortex, 18.5% ± 2.7%
of control upper motor neurons showed tau pS404 staining (positive staining in 7/7 cases)
(Fig. 3C) compared to 96.5% ± 19.8% of ALS upper motor neurons (positive staining in 8/8
cases) (Fig. 3D). Although the number of ALS motor neurons with tau pS404 staining per
mm2 was not significantly different from controls, there was a significant reduction in the
number of tau pS404 negative neurons per mm2 in both the spinal cord (reduced 13-fold, p =
0.008) (Fig. 3E) and motor cortex (reduced 100-fold, p = 0.0003) (Fig. 3F). In addition, small
round deposits of tau pS404 were evident in some ALS lower motor neurons (Fig. 3C inset),
which were not observed in controls.

Absence of fibrillar tau in ALS motor neurons
Modified Bielschowsky silver staining was performed to examine ALS tissue for fibrillar tau.
Despite the fact that abundant NFTs were observed in the positive control sections (inferior
temporal cortex from an AD case), silver staining did not reveal any evidence of fibrils,
including NFTs, in the spinal cord or motor cortex of ALS cases or controls (Supplementary
Fig. 2).
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neuropathological assessment
The number of tau pS214 positive motor neurons per mm2 in the ALS spinal cord negatively
correlated with disease duration (Rho = -0.812 p = 0.02) (Fig. 4A). Conversely, there was a
positive correlation between disease duration and the number of both tau pS214 (Rho = 0.812
p = 0.02) (Fig.4B) and pS404 (Rho = 0.934, p = 0.002) (Fig. 4C) positive motor neurons per
mm2 in the ALS motor cortex. A positive correlation was also observed between motor
neurons with intense pS396 nuclear staining and disease duration in the motor cortex (Rho =
0.778, p = 0.018) (Fig. 4D). There was no relationship between any other pS396 variable and
disease duration or patient age at death, or between the number of tau pS214 and pS404
positive motor neurons per mm2 and patient age at death for either region.

The number of tau pS396 motor neurons per mm2 with nuclear and cytoplasmic staining in
the ALS spinal cord negatively correlated with both the A (Rho = -0.785, p = 0.028) (Fig.
5A) and C (Rho = -0.838, p = 0.015) (Fig. 5B) scores. A negative correlation was also
observed between the number of tau pS396 positive motor neurons per mm2 with cytoplasmic
staining in the ALS motor cortex and the C score (Rho = -0.805, p = 0.022) (Fig. 5C). In
contrast, ALS motor neurons with cytoplasmic tau pS396 staining in the motor cortex
positively correlated with the TDP-43 stage (Rho = 0.866, p = 0.012) (Fig. 5D).

There was no relationship between any other tau pS396 variable or the number of tau pS214
and pS404 positive motor neurons per mm2 with the A, B or C scores, TDP-43 stage or Braak
LB stage in the ALS cases. There was no relationship between the number of tau pS396,
pS214 or pS404 positive motor neurons per mm2 and the A, B or C scores in the control
cases.
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Discussion
In the present study, tau pS396, pS214 and pS404 immunoreactivity was assessed in the
motor neurons from the cervical spinal cord and motor cortex of patients diagnosed with
clinically pure ALS compared to age-and-gender matched healthy controls. For the first time,
tau pS396 staining has been identified in the nucleus of ALS motor neurons. Increased
numbers of motor neurons with cytoplasmic pS396 and pS214 staining were found in ALS
cases compared to controls, and a reduction in tau negative neurons was identified in ALS
compared to controls for all phospho-tau epitopes.
While previous studies suggest that tau may play a role in ALS [14-16, 23, 37], phospho-tau
epitopes have not been assessed in the motor neurons of ALS cases with no co-morbidity,
particularly FTD and cognitive symptoms. This is the first study to report accumulation of
tau, specifically tau pS396 in the nucleus of ALS motor neurons, although PHF1 tau
(S404/S396) has been identified in the nucleus of neurons throughout the brain of a patient
with presenile dementia with motor neuron disease [38], supporting this finding. Previously,
tau has been reported in the nucleus of both neuronal and non-neuronal cells where it is
proposed to have a role in protecting DNA from cellular stress [39-41]. During stress nonphosphorylated tau may also be found in the nucleolus where it has been shown to be
important in heterochromatin stability and ribosomal DNA transcriptional repression [39, 42].
Furthermore, stress induced by glutamate, formaldehyde and Aβ42 has been shown to result
in increased nuclear tau phosphorylated at Thr231 [42], Thr181 and S396 [43], and PHF1
(pS404/S396) [44], respectively. This indicates the existence of different tau species in the
nucleus, and suggests that they may play different roles depending on the type and duration
of stress [42].
Recently, a study assessed human brain for the presence of AT100 tau (pThr212/Ser214)
finding increased nuclear tau with ageing, but a significant reduction in cancer and with
14

progression of AD [45, 46]. AT100 nuclear tau was shown to co-localise with DAPI-positive
chromatin in neurons and was suggested to be important for the cell to maintain control of
genomic DNA [45]. Interestingly, AT100 tau showed a mottled appearance in the nucleus of
aged pyramidal neurons (40-60 years) and increased in intensity in senile pyramidal neurons
(more than 60 years), which also showed light cytoplasmic staining [45]. This is similar to
the findings in the present study of web-like nuclear pS396 tau staining that overlapped with
haematoxylin (stains nuclear chromatin) and the intense nuclear pS396 tau staining that fully
engulfed the nucleus. In addition, the present study also observed motor neurons with both
nuclear and cytoplasmic staining. This may indicate a progression of pS396 tau in ALS motor
neurons, supported by the correlation between increasing intense nuclear tau and disease
duration in the motor cortex. Interestingly, degenerating AD neurons with cytoplasmic NFTs
have been shown to contain almost no nuclear tau [45, 46], in contrast to the present findings
of phosphorylated nuclear tau, coupled with an absence of NFTs in ALS. Similarly, Gallyas
silver staining has previously revealed intra- and extra-neuronal tau aggregates in ALS with
dementia [15, 47] that were absent from clinically pure ALS cases [15]. Western blotting of
ALS and AD brain samples for tau has also revealed different banding patterns in the
insoluble fraction suggesting the presence of different tau isoforms [16]. Comparing the RNA
and protein profiles of motor neurons from clinically pure ALS cases compared to ALSFTLD, FTLD with tau pathology and AD may shed light on the mechanisms involved in
fibrillar tau formation. Furthermore, the negative correlation observed between nuclear and
cytoplasmic tau pS396 in the ALS spinal cord and the A (Aβ/ amyloid plaques) and C
(neuritic plaques) scores, and between cytoplasmic tau pS396 in the ALS motor cortex and
the C score (neuritic plaques), may suggest a protective role for pS396 tau against Aβ
neuropathology. Our findings therefore indicate that the role of phosphorylation at specific
residues of tau should be the subject of future research in ALS. Additional methods including
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the use of recently developed fluorescent dyes and probes may also be considered to further
assess ALS tissue for evidence of tau aggregation [48, 49]. The positive correlation observed
between cytoplasmic tau pS396 in the ALS motor cortex and TDP-43 stage is also of interest
in light of recent work in a mouse model of chronic traumatic encephalopathy which found a
reduction in TDP-43 pathology after elimination of phosphorylated tau [50], and the
subsequent suggestion that that there may be a synergistic toxic relationship between the two
proteins [51]. Taken together, this suggests that different mechanisms may be responsible for
tau accumulation in ALS compared to AD and ALS with dementia/cognitive impairment.
A change in tau phosphorylation is suggested to be responsible for alterations in nuclear tau,
however the exact mechanism of entry into the nucleus is still not known [39]. Studies have
shown that disrupting the balance between tau phosphorylation and O-linked glycosylation
changes tau nuclear localisation [52], and that glycosylation has epitope-specific effects on
levels of tau phosphorylation [53]. Reduced O-glycosylation has been reported in spinal cord
motor neurons from a SOD1 transgenic mouse model of ALS [54], however given the
differences observed in tau accumulation between human ALS tissue and the SOD1 mouse
[23], assessing glycosylation levels in ALS patient tissue would be valuable.
Similar to FTLD tau and AD, phosphorylated tau was observed in the cytoplasm of ALS
motor neurons. However, the staining was diffusely spread throughout the cytoplasm and
didn’t form specific structures, with the exception of round pS404 tau-positive deposits seen
in some ALS lower motor neurons. Cellular stress is known to cause increased tau
phosphorylation, reducing its binding affinity to microtubules, eventually resulting in its
abnormal accumulation in the cytoplasm [55, 56]. In this context, the phosphorylation of tau
at S396, S214 and S404 has been directly linked to the disassociation of tau from the
microtubule complex [7, 57, 58]. Combined with the evidence of cellular stress observed in
the current ALS cohort (swollen motor neurons indicative of chromatolysis), the cytoplasmic
16

accumulation of phosphorylated tau in ALS is consistent with the hypothesis of a stressinduced mislocalisation of tau.
Cytoplasmic accumulation of tau pS214 and pS404 in the motor cortex of ALS patients
positively correlated with disease duration, suggesting an increase in the number of neurons
affected over the disease course. Conversely however, a negative correlation was observed
between cytoplasmic accumulation of tau pS214 and disease duration in the spinal cord. A
positive correlation between intense nuclear tau pS396 staining and disease duration was also
observed in the motor cortex but not in the spinal cord. These region-specific changes may be
due to differences in the severity of motor neuron loss between the spinal cord and motor
cortex, but are also interesting in light of recent studies that have highlighted differences
between the spinal cord and motor cortex in ALS. Positron emission tomography studies
using
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F-fluorodeoxyglucose to assess metabolic activity observed higher tracer uptake in

the spinal cord of ALS patients compared to controls, but reduced uptake in the cortex [59].
Similarly the molecule semaphorin 3A, which has been implicated in the death of motor
neurons, is increased in the motor cortex but reduced in the spinal cord of ALS patients, and
has been shown to enhance survival of spinal cord motor neurons but reduce survival of
cortical neurons [60]. Our data thus supports this different temporal progression of the
mechanisms underlying disease progression in the upper versus lower motor neurons.

Conclusion
This study has identified increased tau phosphorylation in the nucleus and cytoplasm of upper
and lower motor neurons from clinically pure sporadic ALS patients. Tau phosphorylated at
S396 was identified in the nucleus and cytoplasm of ALS motor neurons, while S214 and
S404 were identified only in the cytoplasm of ALS motor neurons. There were region
17

specific differences in the relationships between phosphorylated tau positive motor neurons
and disease duration, supporting a different temporal progression of tau phosphorylation in
the motor neurons from the spinal cord versus motor cortex. Overall this study contributes to
the growing body of evidence suggesting that phosphorylated tau is involved in ALS,
however it remains to be determined whether it is neurodegenerative or neuroprotective.
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List of abbreviations
AD

Alzheimer’s disease

ALS

Amyotrophic lateral sclerosis

FTD

Frontotemporal dementia

FTLD

Frontotemporal lobar degeneration

LB

Lewy Bodies

LMNs

Lower motor neurons

NFTs

Neurofibrillary tangles

NP

Neuritic plaques

PMD

Post mortem delay

pS214

Phosphorylated at serine reside 214

pS396

Phosphorylated at serine reside 396

pS404

Phosphorylated at serine reside 404

TDP-43

TAR DNA-binding protein 43

UMNs

Upper motor neurons
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Figure legends
Fig. 1 Tau pS396 immunoreactivity in motor neurons from control and ALS cases.
Representative micrographs of lower motor neurons (LMNs) in the cervical spinal cord
showing no immunoreactivity in controls (A) but nuclear (B,C) and both nuclear and
cytoplasmic accumulation in ALS (D), and of upper motor neurons (UMNs) in the motor
cortex showing no immunoreactivity in controls (E) but nuclear (F), cytoplasmic (G) and
both nuclear and cytoplasmic accumulation in ALS (H). Comparison between the percentage
of tau pS396 positive and negative motor neurons in control and ALS spinal cord (I) and
motor cortex (J). Comparison between the cellular localisation of tau pS396 in ALS motor
neurons (K). Control n = 7, ALS n = 8. Scale in (H) is equivalent for A-H. Scale bar = 10 μm.

Fig. 2 Tau pS214 immunoreactivity in motor neurons from control and ALS cases.
Representative micrographs of lower motor neurons (LMNs) in the cervical spinal cord
showing no immunoreactivity in controls (A) but cytoplasmic accumulation in ALS (B), and
of upper motor neurons (UMNs) showing no immunoreactivity in controls (C) but
cytoplasmic accumulation in ALS (D). Comparison between the percentage of tau pS214
positive and negative motor neurons in control and ALS spinal cord (E) and motor cortex (F).
Control n = 7, ALS n = 8. Scale in (D) is equivalent for A-D. Scale bar = 10 μm.

Fig. 3 Tau pS404 immunoreactivity in motor neurons from control and ALS cases.
Representative micrographs of lower motor neurons (LMNs) in the cervical spinal cord
showing no immunoreactivity in controls (A), and both diffuse cytoplasmic accumulation (B)
and small round deposits (B inset) in ALS. Representative micrographs of upper motor
neurons (UMNs) in the motor cortex showing no immunoreactivity in controls (C), and
cytoplasmic accumulation in ALS (D). Comparison between the percentage of tau pS404
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positive and negative motor neurons in control and ALS spinal cord (E) and motor cortex (F).
Control n = 7, ALS n = 8. Scale in (D) is equivalent for A-D. Scale bars = 10 μm.

Fig. 4 Linear relationship between tau pS214 immunoreactivity in the lower motor neurons
(LMNs) and disease duration (A), and upper motor neurons (UMNs) and disease duration
(B). Linear relationship between tau pS404 immunoreactivity in the UMNs and disease
duration (C). Linear relationship between UMNs with intense nuclear tau pS396 staining and
disease duration (D). ALS n=8.

Fig. 5 Linear relationship between nuclear and cytoplasmic tau pS396 immunoreactivity in
the lower motor neurons (LMNs) and the A score (Aβ/ amyloid plaques) (A) and the C score
(neuritic plaques) (B). Linear relationship between cytoplasmic tau pS396 immunoreactivity
in the upper motor neurons (UMNs) and the C score (neuritic plaques) (C) and TDP-43 stage
(D). ALS n=8.
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Table 1 Demographic, PMD and neuropathological details of control and ALS cases

Control
1
Control
2
Control
3
Control
4
Control
5
Control
6
Control
7
ALS 1

Female

Age at
death
(years)
72

25

A score
(Aβ/amyloid
plaques)
0

Female

85

N/A

N/A

10

2

1

0

-

-

Male

73

N/A

N/A

9

1

1

0

-

-

Male

67

N/A

N/A

29

3

1

2

-

-

Female

81

N/A

N/A

35

0

1

0

-

-

Male

66

N/A

N/A

20.5

0

1

0

-

-

Male

75

N/A

N/A

34

2

0

0

-

-

Female

72

70

2

8

0

0

0

4

0

ALS 2

Female

70

69

1

5

0

0

0

4

0

ALS 3

Male

66

62

4

24

1

0

0

4

0

ALS 4

Female

81

80

1

19

3

1

3

1

0

ALS 5

Female

82

77

5

24

2

0

2

3

0

ALS 6

Male

75

72

3

29

1

1

1

4

0

ALS 7

Male

72

69

3

31

1

0

0

4

0

ALS 8

Male

67

65

2

35

3

0

2

3

0

Gender

Age at
onset
(years)
N/A

Disease
duration
(years)
N/A

PMD
(hours)

2

C
score
(NPs)
0

TDP43
stage
-

Braak
LB
stage
-

B score
(NFTs)

ALS = Amyotrophic lateral sclerosis. N/A = not applicable. PMD = post mortem delay.
NFTs = neurofibrillary tangles. NPs = neuritic plaques. LB = Lewy body.

Table 2 Demographic and PMD details of control and ALS cohorts
Control

ALS

N (% male)

7 (57%)

8 (50%)a+

Age at death (year (± standard error)

74.1 ± 2

73.1 ± 3a#

Age at onset (year (± standard error)

N/A

70.5 ± 2

Disease duration (year (± standard error)

N/A

2.6 ± 0.5

PMD (hours (± standard error)

23.2 ± 4

21.9 ± 4a#

ALS = amyotrophic lateral sclerosis. N/A = not applicable. ap > 0.05 compared to controls,
Chi square test, #Student’s t test

+

